Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.68 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.60 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18672502 | 0.84 | HRH4 (0.73) | HRH4ADORA2AADORA1AGPAT2TLR8 | |
| SCHEMBL17407824 | 0.84 | HRH4 (0.68) | HRH4ADORA2AADORA1AGPAT2TLR8 | |
| SCHEMBL13875704 | 0.83 | ADORA1 (0.58) | ADORA2AADORA1MAPTAGTR1ALDH1A1 | |
| SCHEMBL21801523 | 0.82 | KDM4E (0.57) | HRH4ADORA2AADORA1AGPAT2TLR8 | |
| SCHEMBL4904514 | 0.82 | ADORA2A (1.00) | HRH4ADORA2AADORA1KDM4EHSP90AA1 | |
| SCHEMBL10565698 | 0.81 | HRH4 (0.64) | HRH4ADORA2AADORA1AGPAT2TLR8 | |
| SCHEMBL4645889 | 0.80 | MAPT (0.62) | HRH4ADORA2AADORA1MAPTAGTR1 | |
| SCHEMBL416616 | 0.80 | MEN1 (0.66) | HRH4ADORA2AADORA1AGPAT2KDM4E | |
| SCHEMBL15757608 | 0.80 | HRH4 (0.77) | HRH4ADORA2AADORA1AGPAT2TLR8 | |
| SCHEMBL15757285 | 0.80 | HRH4 (0.62) | HRH4ADORA2AADORA1AGPAT2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552799-B2 | Triazolone compounds | NXERA PHARMA UK LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | NXERA PHARMA UK LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| CN-115867280-B | 5-Amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer use | 奈克斯拉制药英国有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-115867282-B | 5-Amino-8- (4-pyridyl) - [1,2,4] triazolo [4,3-C ] pyrimidin-3-one compounds for anticancer use | 奈克斯拉制药英国有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-115867550-B | Triazolone compounds | 奈克斯拉制药英国有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4126871-B1 | TRIAZOLONE COMPOUNDS | HEPTARES THERAPEUTICS LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | NXERA PHARMA UK LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021191378-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191376-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191379-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191380-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191380-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| EP-2262811-B1 | 1,2,4-TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE AND PYRAZOLO [4,3-E]-1,2,4-TRIAZOLO [4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8222259-B2 | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222259-B2 | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110152256-A1 | 1,2,4-TRIAZOLO[4,3-c]PYRIMIDIN-3-ONE AND PYRAZOLO[4,3-e]-1,2,4-TRIAZOLO[4,3-c]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-06-23 | — | — | US | disclosed |
| US-20110152256-A1 | 1,2,4-TRIAZOLO[4,3-c]PYRIMIDIN-3-ONE AND PYRAZOLO[4,3-e]-1,2,4-TRIAZOLO[4,3-c]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ADORA2A, ADORA1, ADORA3 | HRH4 1229/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20230271964-A1 | 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER | ADORA2A, ADORA1, ADORA3 | HRH4 767/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | ADORA1, ADORA3, OPRL1 | HRH4 382/4885ADORA2A 4/4885ADORA1 1/4885 |
| US-20110152256-A1 | 1,2,4-TRIAZOLO[4,3-c]PYRIMIDIN-3-ONE AND PYRAZOLO[4,3-e]-1,2,4-TRIAZOLO[4,3-c]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | HRH4 429/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-12552799-B2 | Triazolone compounds | ADORA1, ADRA2C, ADORA2A | HRH4 124/4885ADORA2A 3/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.